Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07519616
NA

Effect of Escherichia Coli 5C (Colipral®) on Post-Colonoscopy Gastrointestinal Symptoms

Sponsor: Liaquat University of Medical & Health Sciences

View on ClinicalTrials.gov

Summary

This prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of Escherichia coli 5C (Colipral®) in adult patients undergoing diagnostic colonoscopy. Participants will be randomized in a 1:1 ratio to receive either Colipral® or placebo for 14 days immediately after colonoscopy. The study aims to determine whether Colipral® reduces post-colonoscopy gastrointestinal symptoms compared with placebo, using validated symptom and stool assessment tools, patient-reported global improvement, and safety monitoring.

Official title: Evaluation of the Effectiveness of Escherichia Coli 5C in the Management of Post-Colonoscopy Symptoms: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

160

Start Date

2026-04-27

Completion Date

2026-10-30

Last Updated

2026-04-09

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

Colipral®

Dietary supplement containing Escherichia coli 5C (Colipral®)

OTHER

Placebo

Matching placebo

Locations (1)

University of Urbino Carlo Bo, Urbino, Italy

Urbino, Italy